xRead - September 2022

Wise et al.

Page 382

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.4. Evidence for the use of leukotriene receptor antagonists as monotherapy in the treatment of allergic rhinitis (Level 1a and 1b studies only) Study Year LOE Study design Study groups Clinical endpoint Conclusion Devillier et al. 1332 2014 1a SR of RCTs, with homogeneity 1 LTRA; 2 SLIT; 3 Placebo Symptoms SLIT superior clinical effect to LTRA. LTRA with clinical effect compared to placebo. Goodman et al. 1347 2008 1a SR of RCTs, with homogeneity 1 Montelukast; 2 Levocetirizine; 3 Desloratadine; 4 Fexofenadine Symptoms, cost Montelukast with higher incremental cost-effectiveness ratio than levocetirizine and desloratadine. Grainger & Drake Lee 1333 2006 1a SR of RCTs, with homogeneity 1 Montelukast; 2 Oral antihistamine; 3 INCS; 4 Placebo Symptoms, QOL Montelukast improved symptoms and QOL compared to placebo, and was inferior to oral antihistamines and INCS. Rodrigo & Yanez 1334 2006 1a SR of RCTs, with homogeneity 1 LTRA; 2 Oral antihistamine; 3 INCS; 4 Placebo Symptoms, QOL LTRA improved symptoms and QOL compared to placebo, was equally effective to oral antihistamine, and inferior to INCS. Wilson et al. 1300 2004 1a SR of RCTs, with homogeneity 1 Montelukast; 2 Oral antihistamine; 3 INCS; 4 Placebo Symptoms, QOL Montelukast improved QOL compared to placebo, and was inferior to antihistamines and INCS. Gonyeau & Partisan 1335 2003 1a SR of RCTs, with homogeneity 1 Montelukast; 2 INCS; 3 Placebo Symptoms Montelukast was more effective than placebo in reducing symptoms, but was inferior to INCS. Endo et al. 1336 2012 1b RCT 1 Pranlukast; 2 Placebo Symptoms Pranlukast prevented and reduced symptoms compared to placebo after artificial introduction of allergen.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.